CellCentric Ltd.

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
CBP/p300 (bromodomain)Small molecule
Acute Myeloid LeukemiaMultiple Myeloma

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
InobrodibPhase 1/2Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome …
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch
2029 (2)
November 2029 (1)
InobrodibPhase 3Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Est. primary completion 2029-11 · NCT07772024 · CT.gov ↗
What to watch
December 2029 (1)
InobrodibPhase 2Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Est. primary completion 2029-12-01 · NCT07096778 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.